AC BioScience Ltd is a clinical stage biotechnology company dedicated to developing innovative therapies for the treatment of tumoral and immunological pathologies.
Products, services, technology
S1P metabolites (ACB2003.4) as an angiogenic therapy for solid hypoxic cancers. Start with clinical trials Phase 2a in early 2023 for a combination treatment of metastatic pancreatic adenocarcinoma.
Beta-carboline derivative (ACB1801) to enhance the efficacy of checkpoint-inhibitor immune-therapy.